CompletedNot Applicable

Impact of Prior SGLT2 Inhibitors Use on the Development and Progression of Sepsis-Associated Acute Kidney Injury

Saudi Arabia664 participantsStarted 2024-04-01

Plain-language summary

The primary objective of this study is to investigate whether using SGLT2i may be associated with decreased incidence of sepsis-induced AKI or not.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All adult (≥ 18 year) patients who were admitted to ICU with sepsis syndromes (sepsis or septic shock), according to sepsis-3 definition. Exclusion Criteria: * Missing data * Renal transplant or tumor * Solitary kidney * Established CKD * Obstructive uropathy * Renal artery stenosis * Pregnancy

What they're measuring

Odds of sepsis-associated acute kidney injury (AKI) in patients with prior use of SGLT2 inhibitors (SGLT2i)

Timeframe: The exposure window for SGLT2i use will be defined as any use within 90 days prior to the onset of sepsis. The outcome (sepsis-associated AKI) will be evaluated during the index hospitalization for sepsis.

Trial details

NCT IDNCT06902493

SponsorUniversity of Jazan

Sponsor typeOTHER_GOV

Study typeOBSERVATIONAL

Primary completion2025-03-01

View on ClinicalTrials.gov More Sepsis trials